CTLA4 and melanoma: Research shows that cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitors, the first ICI approved by the U.S. Food and Drug Administration (FDA), can improve survival rates in patients with advanced melanoma (43, 44).